Document 0104
 DOCN  M95A0104
 TI    Zidovudine treatment prolongs survival and decreases virus load in the
       central nervous system of rhesus macaques infected perinatally with
       simian immunodeficiency virus.
 DT    9510
 AU    Rausch DM; Heyes MP; Murray EA; Eiden LE; Section on Molecular
       Neuroscience, National Institute of Mental; Health, National Institutes
       of Health, Bethesda, MD 20892, USA.
 SO    J Infect Dis. 1995 Jul;172(1):59-69. Unique Identifier : AIDSLINE
       MED/95318560
 AB    To assess the potential therapeutic effects of zidovudine, rhesus
       macaques were inoculated with simian immunodeficiency virus (SIV) strain
       SMM/B670 at birth and infused either continuously or intermittently with
       zidovudine for 6-7 months. Zidovudine did not prevent infection but did
       significantly increase survival time, which was associated with lower
       serum p26 viral core antigen levels, a lower virus burden in the
       cerebrospinal fluid (CSF), and lower CSF quinolinic acid levels than in
       untreated monkeys. Two of 5 infected, untreated monkeys developed motor
       impairment within 6 months following infection, whereas motor
       impairments did not occur in infected, zidovudine-treated monkeys until
       after the drug was discontinued. Zidovudine treatment was well tolerated
       by rhesus infants with minimal, transient side effects. These results
       demonstrate that zidovudine treatment significantly decreases virus load
       within the central nervous system (CNS) and delays the onset of CNS
       dysfunction and immune disease in rhesus monkeys perinatally infected
       with SIV.
 DE    Animal  Central Nervous System/*VIROLOGY  Cerebrospinal Fluid/*VIROLOGY
       CD4-CD8 Ratio  CD4-Positive T-Lymphocytes/IMMUNOLOGY  CD8-Positive
       T-Lymphocytes/IMMUNOLOGY  Death  Female  Macaca mulatta  Male  Motor
       Activity/DRUG EFFECTS  Quinolinic Acid/CEREBROSPINAL FLUID  Simian
       Acquired Immunodeficiency Syndrome/*DRUG THERAPY/PATHOLOGY/
       PHYSIOPATHOLOGY  SIV/*ISOLATION & PURIF/PHYSIOLOGY  Time Factors  Viral
       Core Proteins/BLOOD  Zidovudine/BLOOD/*THERAPEUTIC USE  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).